1 | 1 | | 81R4236 JSC-D |
---|
2 | 2 | | By: Woolley H.B. No. 1764 |
---|
3 | 3 | | |
---|
4 | 4 | | |
---|
5 | 5 | | A BILL TO BE ENTITLED |
---|
6 | 6 | | AN ACT |
---|
7 | 7 | | relating to the regulation of the use of human cells and tissue, |
---|
8 | 8 | | including a ban on human cloning; providing penalties. |
---|
9 | 9 | | BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
---|
10 | 10 | | SECTION 1. Subtitle H, Title 2, Health and Safety Code, is |
---|
11 | 11 | | amended by adding Chapter 176 to read as follows: |
---|
12 | 12 | | CHAPTER 176. BIOMEDICAL RESEARCH OVERSIGHT |
---|
13 | 13 | | SUBCHAPTER A. GENERAL PROVISIONS |
---|
14 | 14 | | Sec. 176.001. DEFINITIONS. In this chapter: |
---|
15 | 15 | | (1) "Embryo" means an organism from the single cell |
---|
16 | 16 | | stage to eight weeks of development. |
---|
17 | 17 | | (2) "Fertilization" means the fusion of a female germ |
---|
18 | 18 | | cell containing a haploid nucleus with a male gamete or sperm cell. |
---|
19 | 19 | | (3) "Human cloning" means implanting or attempting to |
---|
20 | 20 | | implant into a uterus or the functional equivalent of a uterus a |
---|
21 | 21 | | human embryo created by a method other than fertilization. |
---|
22 | 22 | | (4) "Oocyte" means the female germ cell, the egg. |
---|
23 | 23 | | [Sections 176.002-176.050 reserved for expansion] |
---|
24 | 24 | | SUBCHAPTER B. HUMAN CLONING |
---|
25 | 25 | | Sec. 176.051. HUMAN CLONING PROHIBITED. A person may not |
---|
26 | 26 | | engage in or attempt to engage in human cloning. |
---|
27 | 27 | | Sec. 176.052. LICENSED VIOLATORS. A person licensed by a |
---|
28 | 28 | | state agency as a health care practitioner or health care facility |
---|
29 | 29 | | who violates Section 176.051 is subject to the same consequence, |
---|
30 | 30 | | other than a civil penalty, that the person would be subject to if |
---|
31 | 31 | | the person had violated the licensing law applicable to the person |
---|
32 | 32 | | or rules adopted under that law. |
---|
33 | 33 | | Sec. 176.053. CIVIL PENALTY. (a) A person who violates |
---|
34 | 34 | | Section 176.051 is liable to the state for a civil penalty of not |
---|
35 | 35 | | more than $10 million for each violation. |
---|
36 | 36 | | (b) The amount of the penalty shall be based on: |
---|
37 | 37 | | (1) the seriousness of the violation; |
---|
38 | 38 | | (2) the history of previous violations; |
---|
39 | 39 | | (3) the amount necessary to deter a future violation; |
---|
40 | 40 | | and |
---|
41 | 41 | | (4) any other matter that justice may require. |
---|
42 | 42 | | (c) The attorney general may sue to collect a civil penalty |
---|
43 | 43 | | under this section. In the suit the attorney general may recover |
---|
44 | 44 | | the reasonable expenses incurred in obtaining the penalty, |
---|
45 | 45 | | including investigation and court costs, reasonable attorney's |
---|
46 | 46 | | fees, witness fees, and other expenses. |
---|
47 | 47 | | Sec. 176.054. CRIMINAL OFFENSE. A person commits an |
---|
48 | 48 | | offense if the person intentionally engages in or attempts to |
---|
49 | 49 | | engage in human cloning. An offense under this section is a felony |
---|
50 | 50 | | of the first degree. |
---|
51 | 51 | | [Sections 176.055-176.100 reserved for expansion] |
---|
52 | 52 | | SUBCHAPTER C. RESEARCH USING CERTAIN HUMAN CELLS OR TISSUES |
---|
53 | 53 | | Sec. 176.101. PROTECTION OF RESEARCH. This chapter does |
---|
54 | 54 | | not restrict or prohibit: |
---|
55 | 55 | | (1) scientific research, including nuclear |
---|
56 | 56 | | transplantation, to develop regenerative or reparative medical |
---|
57 | 57 | | therapies or treatments; or |
---|
58 | 58 | | (2) any other research not specifically prohibited by |
---|
59 | 59 | | this chapter. |
---|
60 | 60 | | Sec. 176.102. RESEARCH OVERSIGHT. Research described by |
---|
61 | 61 | | Section 176.101(1) must be: |
---|
62 | 62 | | (1) conducted with full consideration for the ethical |
---|
63 | 63 | | and medical implications of the research; and |
---|
64 | 64 | | (2) reviewed, in each case, by an institutional review |
---|
65 | 65 | | board for compliance with applicable state and federal law and |
---|
66 | 66 | | after consideration of the guidelines developed under Section |
---|
67 | 67 | | 176.103. |
---|
68 | 68 | | Sec. 176.103. ADVISORY COMMITTEE ON RESEARCH TO DEVELOP |
---|
69 | 69 | | REGENERATIVE OR REPARATIVE MEDICAL THERAPIES OR TREATMENTS. (a) |
---|
70 | 70 | | The executive commissioner of the Health and Human Services |
---|
71 | 71 | | Commission shall establish an advisory committee to develop |
---|
72 | 72 | | guidelines for research described by Section 176.101(1). |
---|
73 | 73 | | (b) The advisory committee consists of members appointed by |
---|
74 | 74 | | the executive commissioner of the Health and Human Services |
---|
75 | 75 | | Commission as follows: |
---|
76 | 76 | | (1) seven scientists with experience in biomedical |
---|
77 | 77 | | research in the fields of cell differentiation, nuclear |
---|
78 | 78 | | reprogramming, tissue formation and regeneration, stem cell |
---|
79 | 79 | | biology, developmental biology, regenerative medicine, or related |
---|
80 | 80 | | fields; |
---|
81 | 81 | | (2) one representative from each health science center |
---|
82 | 82 | | in this state; |
---|
83 | 83 | | (3) one person who is a member of or leader in the |
---|
84 | 84 | | biotechnology industry; |
---|
85 | 85 | | (4) one medical ethicist; |
---|
86 | 86 | | (5) one person with a background in legal issues |
---|
87 | 87 | | related to research described by Section 176.101(1), in vitro |
---|
88 | 88 | | fertilization, or family law, as it applies to the donation of |
---|
89 | 89 | | embryos and oocytes; and |
---|
90 | 90 | | (6) one person who is a member or leader of a religious |
---|
91 | 91 | | organization. |
---|
92 | 92 | | (c) The advisory committee shall revise and update the |
---|
93 | 93 | | guidelines developed under this section as necessary. |
---|
94 | 94 | | (d) The advisory committee may work with existing |
---|
95 | 95 | | institutional review boards in developing guidelines. |
---|
96 | 96 | | (e) Section 2110.008, Government Code, does not apply to the |
---|
97 | 97 | | advisory committee. |
---|
98 | 98 | | Sec. 176.104. VOLUNTARY DONATION OF OOCYTES. A person may |
---|
99 | 99 | | not use an oocyte in nuclear transplantation research unless the |
---|
100 | 100 | | oocyte was donated voluntarily by and with the informed consent of |
---|
101 | 101 | | the woman donating the oocyte. |
---|
102 | 102 | | [Sections 176.105-176.150 reserved for expansion] |
---|
103 | 103 | | SUBCHAPTER D. PROHIBITED PURCHASE OR SALE; CRIMINAL PENALTY |
---|
104 | 104 | | Sec. 176.151. PURCHASE OR SALE OF OOCYTE. (a) A person may |
---|
105 | 105 | | not purchase, sell, or otherwise transfer for valuable |
---|
106 | 106 | | consideration a human oocyte. |
---|
107 | 107 | | (b) In this section, "valuable consideration" does not |
---|
108 | 108 | | include reasonable payments: |
---|
109 | 109 | | (1) associated with the transportation, processing, |
---|
110 | 110 | | preservation, or storage of a human oocyte; or |
---|
111 | 111 | | (2) to compensate a donor for expenses directly |
---|
112 | 112 | | associated with the donation. |
---|
113 | 113 | | (c) A person commits an offense if the person knowingly |
---|
114 | 114 | | violates Subsection (a). An offense under this subsection is a |
---|
115 | 115 | | felony of the first degree. |
---|
116 | 116 | | SECTION 2. (a) The executive commissioner of the Health and |
---|
117 | 117 | | Human Services Commission shall appoint members to the advisory |
---|
118 | 118 | | committee as required by Section 176.103, Health and Safety Code, |
---|
119 | 119 | | as added by this Act, not later than November 1, 2009. |
---|
120 | 120 | | (b) The advisory committee shall adopt research guidelines |
---|
121 | 121 | | as required by Section 176.103, Health and Safety Code, as added by |
---|
122 | 122 | | this Act, not later than June 1, 2010. |
---|
123 | 123 | | SECTION 3. This Act takes effect September 1, 2009. |
---|